Immutep Limited (IMMP) Announces Licensing Partner GSK to Discontinue Ulcerative Colitis Phase II Clinical Trial Evaluating GSK2831781

Go back to Immutep Limited (IMMP) Announces Licensing Partner GSK to Discontinue Ulcerative Colitis Phase II Clinical Trial Evaluating GSK2831781

Ulcerative Colitis Phase II Study of GSK2831781 Discontinued

January 21, 2021 5:40 PM EST

Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, advises that one of its licensing partners, GSK, has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immuteps IMP731 antibody), in patients with active... More